Melqart Asset Management UK Ltd Has $62.40 Million Stock Position in Catalent, Inc. (NYSE:CTLT)

Melqart Asset Management UK Ltd increased its position in Catalent, Inc. (NYSE:CTLT - Free Report) by 159.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,030,240 shares of the company's stock after purchasing an additional 632,515 shares during the quarter. Catalent makes up 5.6% of Melqart Asset Management UK Ltd's portfolio, making the stock its 7th biggest position. Melqart Asset Management UK Ltd owned 0.57% of Catalent worth $62,402,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CTLT. Athos Capital Ltd bought a new stake in Catalent in the 3rd quarter valued at approximately $6,009,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Catalent during the 3rd quarter worth approximately $1,131,000. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Catalent by 3.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company's stock worth $24,550,000 after acquiring an additional 14,373 shares during the last quarter. Quest Partners LLC increased its holdings in shares of Catalent by 289.8% during the 3rd quarter. Quest Partners LLC now owns 49,300 shares of the company's stock worth $2,986,000 after acquiring an additional 36,652 shares during the last quarter. Finally, Natixis Advisors LLC acquired a new position in shares of Catalent during the 3rd quarter worth approximately $1,287,000.

Insider Activity

In related news, Director Michelle R. Ryan sold 2,800 shares of the firm's stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares of the company's stock, valued at $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider David Mcerlane sold 1,994 shares of the firm's stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now directly owns 36,304 shares of the company's stock, valued at $2,177,150.88. This represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,114 shares of company stock valued at $305,931. Company insiders own 0.31% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on CTLT. William Blair reaffirmed a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. StockNews.com raised Catalent from a "sell" rating to a "hold" rating in a report on Monday. Baird R W downgraded Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. Finally, Robert W. Baird restated a "neutral" rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. Eight analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $63.40.

Catalent Trading Up 0.2 %

Catalent stock traded up $0.14 during trading hours on Wednesday, hitting $61.84. The stock had a trading volume of 1,797,071 shares, compared to its average volume of 2,039,532. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The stock has a market cap of $11.22 billion, a price-to-earnings ratio of -27.38, a P/E/G ratio of 2.44 and a beta of 1.15. Catalent, Inc. has a one year low of $36.74 and a one year high of $62.08. The business's 50 day simple moving average is $59.96 and its 200-day simple moving average is $58.60.

Catalent (NYSE:CTLT - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company's quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.10) EPS. On average, equities analysts predict that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.